These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8766103)

  • 1. [Serum concentrations of the MCA tumor marker during pregnancy].
    Pütz I; Lang G; Winkler M; Rath W
    Zentralbl Gynakol; 1996; 118(7):409-11. PubMed ID: 8766103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer markers during normal pregnancy.
    Botsis D; Sarandakou A; Kassanos D; Kontoravdis A; Rizos D; Protonotariou E; Phocas I; Creatsas G
    Anticancer Res; 1999; 19(4C):3539-41. PubMed ID: 10629649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MCA performance in preoperative breast cancer patients.
    Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
    Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of a new tumor marker (M.C.A.) in the breast cancer follow-up.
    Cappellari A; Bagarella M; Corradi G
    Boll Ist Sieroter Milan; 1990; 69(1):315-8. PubMed ID: 2102115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor markers MCA and CA-125 in the diagnosis and monitoring of breast cancer].
    Shakhtarin VV; Izotova IA; Parshkov EM; Chekin SIu; Simakova GM
    Vopr Onkol; 1992; 38(4):433-9. PubMed ID: 1300737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of a new tumour marker TAG 12 in breast cancer.
    Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P
    Anticancer Res; 1991; 11(2):805-8. PubMed ID: 2064336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new tumor marker MCA in breast cancer diagnosis.
    Eskelinen M; Tikanoja S; Collan Y
    Anticancer Res; 1988; 8(4):665-8. PubMed ID: 3178156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The serum tumor marker M3/M21 in the follow-up of breast cancer patients.
    Tempfer C; Hanzal E; Zeillinger R; Koelbl H; Dadak C; Kainz C
    Anticancer Res; 1996; 16(5B):3049-52. PubMed ID: 8920765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of mucinous-like cancer antigen (MCA) in women with breast disease: preliminary results.
    Valenti G; Zanardi S; Valtolina M; Bombardieri E; Boccardo F
    Cancer Detect Prev; 1991; 15(4):285-9. PubMed ID: 1794135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of CA 15-3 and MCA monoclonal antibody assays in the detection of primary and recurrent breast cancer.
    Pirolo F; Pacini P; Borsotti M; la Morgia R; Mungai R; Cappellini M; Cardona G; Cataliotti L; Marzano S; Neri B
    Anticancer Res; 1991; 11(2):729-31. PubMed ID: 2064326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of tumour markers TAG 12 with CA 15-3 and MCA in breast cancer diagnosis.
    Eskelinen M; Hippelainen M; Salmela E; Paajanen H; Carlsson L; Jonsson P; Alhava E
    Anticancer Res; 1992; 12(1):39-42. PubMed ID: 1567179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
    Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
    Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
    Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
    Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of four serological tumor markers for the detection of breast cancer.
    Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
    Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pre- and post-therapeutic serum concentrations of mucin-like carcinoma-associated antigen in patients with breast cancer].
    Fuith LC; Artner-Dworzak E; Schröcksnadel H; Müller-Holzner E; Daxenbichler G; Heim K
    Gynakol Rundsch; 1989; 29 Suppl 2():397-9. PubMed ID: 2613061
    [No Abstract]   [Full Text] [Related]  

  • 18. Tissue polypeptide specific antigen (TPS) throughout normal pregnancy.
    Kassanos D; Botsis D; Rizos D; Kontoravdis A; Sikiotis K; Phocas I; Sarandakou A; Creatsas G
    Anticancer Res; 2000; 20(3B):2129-31. PubMed ID: 10928165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients.
    Stieber P; Molina R; Chan DW; Fritsche HA; Beyrau R; Bonfrer JM; Filella X; Gornet TG; Hoff T; Jäger W; van Kamp GJ; Nagel D; Peisker K; Sokoll LJ; Troalen F; Untch M; Domke I
    Clin Lab; 2003; 49(1-2):15-24. PubMed ID: 12593471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Considerations in rational use of tumor markers in breast carcinoma].
    Crombach G
    Praxis (Bern 1994); 1998 Apr; 87(17):589-94. PubMed ID: 9623326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.